Validation of a High-Risk MDS Prognostic Model (2011 ASH Conference)

VIDEO | 01:00

Selection of the appropriate therapy for patients with myelodysplastic syndromes depends heavily on the predicted prognosis of each afflicted individual. Prognostic scoring systems help stratify patients into risk groups, but outcomes can be highly variable even within these groups.

Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system’s ability to identify higher-risk MDS patients among those with lower International Prognostic Scoring System (IPSS) risk and demonstrates that point mutations are common in this cohort, associate with specific clinical features, and independently provide both favorable and adverse prognostic information.